Hims Stock: Executive Sells Shares During Important Events

July 30, 2025: the Chief Legal Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 2,572 shares of Class A Common Stock on July 28, 2025, as part of a recent Hims stock deal. The selling brought in $150,976 at $58.70 per share. This deal was made according to a Rule 10b5-1 trading plan that went into effect on August 28, 2024. The Securities and Exchange Commission received an official report of the deal in a Form 4 filing. After this sell, Boughton now owns 155,593 shares of Hims & Hers Health, Inc.

In other recent news about Hims & Hers, the company says that its compounded GLP-1 weight loss therapies are showing good results. Customers who used these therapies lost an average of 10.3% of their body weight over the course of six months. The company also pointed out that 75% of customers stayed with the program, which is much higher than the usual dropout rates for GLP-1 solutions that are available for sale. Hims & Hers wants to grow its business by entering the Canadian market by 2026. Once Novo Nordisk’s patent protection in that area runs out, the company plans to sell generic semaglutide.

Also Read: The price of Bitcoin drops today,Before the Fed makes its decision

Hims stock has come under fire from financial analysts, even though the company has made good progress in both clinical and business growth. BofA Securities has kept the stock at an Underperform rating because they are worried about the chances of lawsuits and the company’s full-year guidance being under pressure because of a mix of business prospects. Morgan Stanley also kept its Equalweight rating, saying that the telehealth company’s growth was decreasing and that app downloads were down.

CEO Andrew Dudum gave further information on the company’s strategic landscape when he talked about ending a partnership with Novo Nordisk. The end of this partnership was due to arguments about Hims & Hers’ continued sale of compounded semaglutide. These changes give a full picture of the company’s current management activities, its performance in important health areas, and the ongoing evaluations of Hims stock by market experts.